Browse by Poster Presenter

Schedule at a Glance

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

F
Fabbroni, Chiara

Fondazione IRCCS Istituto nazionale dei tumori
(P 308) IMPACT OF PSOAS MUSCLE RESECTION ON OUTCOMES IN PRIMARY RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA
Chiara Fabbroni
Favorite
(P 331) MAINTENANCE THERAPY (M-TP) WITH DACARBAZINE (DTIC) AFTER FIRST-LINE ANTHRACYCLINE-BASED DOUBLET IN ADVANCED LEIOMYOSARCOMA (LMS) PATIENTS (PTS): OUTCOMES OF A CASE SERIES IN A SINGLE REFERRAL CENTER
Chiara Fabbroni
Favorite
Facchetti, Fabio

Spedali Civili di Brescia
(P 458) BETWEEN LYMPHOMAS AND SARCOMAS: A RETROSPECTIVE, MULTI-INSTITUTIONAL STUDY FROM THE ITALIAN SARCOMA GROUP (ISG) ON HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS (HDCN)
Fabio Facchetti
Favorite
Facklam, Amanda

Pyxis Oncology
(P 29) ANTI-TUMOR ACTIVITY OF MICVOTABART PELIDOTIN IS ASSOCIATED WITH ENZYME GENE EXPRESSION IN PATIENT-DERIVED XENOGRAFT SARCOMA MODELS
Amanda Facklam
Favorite
Faco, Alexandre

MUHC - McGill University Health Center
(P 120) SURVIVAL OUTCOMES AND ROLE OF CHEMOTHERAPY IN PATIENTS OLDER THAN 40 YEARS WITH OSTEOSARCOMA (OLD-SARC STUDY).
Alexandre Faco
Favorite
Fagundes, Djalma

UNIFESP
(P 347) SURVIVAL ANALYSIS AND PROGNOSTIC FACTORS OF SOFT TISSUE SARCOMAS OF THE TRUNK AND EXTREMITIES TREATED BETWEEN 2010 AND 2015: EXPERIENCE OF THE BRAZILIAN NATIONAL CANCER INSTITUTE
Djalma Fagundes
Favorite
Fairweather, Mark

Brigham and Women's Hospital
(P 228) FREQUENCY AND CLARITY OF SURGICAL GOALS FOR TUMOR RESECTION IN ADVANCED SARCOMA
Mark Fairweather
Favorite
Falkenhorst, Johanna

West German Cancer Center, University Duisburg-Essen
(P 182) USING IN VITRO MODELS TO PREDICT IMATINIB RESPONSES OF PDGFRA EXON 18-MUTANT GIST
Johanna Falkenhorst
Favorite
Falkowski, Slawomir

Maria Sklodowska-Curie National Research Institute of Oncology
(P 146) LOCALISED CHONDROSARCOMA PERIOPERATIVE TREATMENT: REAL-WORLD OUTCOMES AND CHALLENGES ACROSS HISTOLOGIC SUBTYPES
Slawomir Falkowski
Favorite
(P 152) EFFICACY OF PALLIATIVE CHEMOTHERAPY AND LOCAL TREATMENTS IN ADVANCED CHONDROSARCOMA: A SUBTYPE-SPECIFIC RETROSPECTIVE ANALYSIS
Slawomir Falkowski
Favorite
Fanburg-Smith, Julie

University of Virginia
(P 199) CHARACTERISTICS OF AN IMMUNOHISTOCHEMICAL AND MOLECULARLY DISCORDANT POPULATION OF GIST PATIENTS: A SINGLE CENTER RETROSPECTIVE REVIEW
Julie Fanburg-Smith
Favorite
Fan, Jiaqian

MD Anderson Cancer Center
(P 47) EWSR1::WT1 FUSION ONCOPROTEIN ACTIVITY SHAPES LINEAGE HETEROGENEITY IN DESMOPLASTIC SMALL ROUND CELL TUMORS
Jiaqian Fan
Favorite
Fanta, Paul T.

University of California San Diego
(P 179) NEOADJUVANT AVAPRITINIB IN PDGFRA-MUTANT GIST: NEAR COMPLETE PATHOLOGICAL RESPONSES AT THE COST OF HIGH ADVERSE EVENT RATES
Paul T. Fanta
Favorite
(P 180) COMPARATIVE EFFICACY OF GENERIC AND BRAND-NAME IMATINIB IN NEOADJUVANT TREATMENT OF KIT EXON 11 MUTANT GIST
Paul T. Fanta
Favorite
Fantoni, Leonardo

IRCCS Rizzoli Orthopaedic Institute
(P 18) ESTABLISHMENT AND CHARACTERIZATION OF A NOVEL PRIMARY CELL LINE FROM A BONE METASTASIS OF OSTEOSARCOMA
Leonardo Fantoni
Favorite
Fan, Wenyi

Moffitt Cancer Center
(P 394) DUAL OR TRIMODALITY THERAPY VERSUS SURGERY ALONE IN RADIATION-ASSOCIATED ANGIOSARCOMA OF THE BREAST
Wenyi Fan
Favorite
Fan, Zhengfu

Department of Bone and Soft Tissue Tumour, Peking University Cancer Hospital, Beijing, China
(P 361) PEXIDARTINIB FOR THE TREATMENT OF TENOSYNOVIAL GIANT CELL TUMORS: CLINICAL EXPERIENCE FROM FIVE CHINESE PATIENTS
Zhengfu Fan
Favorite
Farley, Lauren

Surgical Oncology, Department of Surgery, University of California, Davis
(P 244) INTRATUMORAL TIGIT BLOCKADE AUGMENTS ANTI-TUMOR RESPONSES AND BYPASSES HYPERFUNCTIONALITY OF PERIPHERAL TIGIT+ NK CELLS IN MOUSE AND HUMAN MODELS OF BONE AND SOFT TISSUE SARCOMA
Lauren Farley
Favorite
Farmer, Rebecca

University of Kansas Medical Center
(P 366) WOUND COMPLICATIONS AFTER ULTRA-HYPOFRACTIONATED NEOADJUVANT RADIATION FOR SOFT TISSUE SARCOMA: WHAT IS OPTIMAL SURGICAL TIMING?
Rebecca Farmer
Favorite
Farmer, Trevor

West Virginia University Department of Surgery
(P 30) MYELOPEROXIDASE AS A POTENTIAL THERAPEUTIC TARGET IN SOFT TISSUE SARCOMA
Trevor Farmer
Favorite
Faron, Matthieu

Gustave Roussy Cancer Campus
(P 299) RECURRENCES AFTER PRIMARY RPS SURGERY IN A HIGH-VOLUME SARCOMA CENTER: A RETROSPECTIVE ANALYSIS ON 402 PATIENTS
Matthieu Faron
Favorite
Farooqi, Ahsan

MD Anderson Cancer Center
(P 242) IMMUNE PROFILING OF UNDIFFERENTIATED PLEOMORPHIC SARCOMAS REVEALS DISTINCT PROGNOSTIC SUBGROUPS
Ahsan Farooqi
Favorite
Farrelly, Eileen

Cencora, Inc.
(P 368) ASSESSMENT OF PAIN DIAGNOSIS AND PAIN MEDICATION USE IN ADULTS TREATED WITH NIROGACESTAT: A UNITED STATES REAL-WORLD ANALYSIS
Eileen Farrelly
Favorite
Faulkner, Lisa

Clear Cell Sarcoma Foundation
(P 450) OUTCOMES IN CLEAR CELL SARCOMA: UPDATED INSIGHTS FROM ELECTRONIC HEALTH RECORDS IN A PATIENT-LED REGISTRY
Lisa Faulkner
Favorite
FAU, Magali

Institut Bergonié
(P 390) USE OF DERMAL TEMPLATE FOR NERVE PROTECTION IN LIMB-SPARING SURGERY FOR SOFT TISSUE SARCOMAS: PRELIMINARY EXPERIENCE FROM INSTITUT BERGONIE
Magali FAU
Favorite
Faust, Caitlin

Huntsman Cancer Institute
(P 01) FEASIBILITY OF A QUANTITATIVE METHYLATION-BASED CTDNA ASSAY IN PATIENTS WITH ADVANCED SARCOMAS
Caitlin Faust
Favorite
Favini, Enrica

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 452) EFFECTIVENESS OF ERIBULIN FOR MYXOID PLEOMORPHIC LIPOSARCOMA: INSIGHTS FROM A PATIENT-DERIVED MODEL AND CLINICAL TRANSLATION IN A PATIENT WITH ADVANCED DISEASE
Enrica Favini
Favorite
Fazelzad, Rouhi

Princess Margaret Cancer Centre
(P 346) SURROGATE ENDPOINTS FOR OVERALL SURVIVAL IN ADVANCED SOFT TISSUE SARCOMA TRIALS: A SYSTEMATIC REVIEW AND META-ANALYSIS
Rouhi Fazelzad
Favorite
Federation, Alex

TalusBio
(P 260) MECHANISM AND EFFICACY OF ANTHRACYCLINE MEDIATED EPIGENETIC DISRUPTION IN BONE SARCOMAS.
Alex Federation
Favorite
Federman, Noah

University of California, Los Angeles
(P 413) EFFICACY OF NIROGACESTAT IN PATIENTS WITH DESMOID TUMORS AND PRESENCE OR ABSENCE OF POOR PROGNOSTIC FACTORS: POST HOC ANALYSES OF THE PHASE 3 DEFI TRIAL
Noah Federman
Favorite
(P 417) EFFICACY AND SAFETY OF LAROTRECTINIB (LARO) IN PATIENTS (PTS) WITH TRK FUSION SARCOMAS
Noah Federman
Favorite
Fehnel, Katie

Boston Children's Hospital
(P 290) CLINICAL OUTCOMES AFTER RADIOTHERAPY FOR PATIENTS WITH POORLY DIFFERENTIATED CHORDOMA
Katie Fehnel
Favorite
Feinberg, Galina

Hemato-Oncology Laboratory, Schneider Children's Medical Center of Israel, Petach Tikva, Israel.
(P 06) RAPID, POINT-OF-CARE DNA METHYLATION & MOLECULAR LANDSCAPE BASED SARCOMA CLASSIFICATION
Galina Feinberg
Favorite
Feinberg, Tamar

Memorial Sloan Kettering Cancer Center
(P 26) DEVELOPING AN ORTHOTOPIC MODEL OF DESMOPLASTIC SMALL ROUND CELL TUMOR
Tamar Feinberg
Favorite
(P 237) DEVELOPMENT OF EPHA2 CAR T CELL THERAPY FOR OSTEOSARCOMA
Tamar Feinberg
Favorite
Felser, Brandi

Sarcoma Foundation of America
(P 209) SARCOMA PATIENT COMMUNITY DATA COLLABORATION TO ADVANCE RESEARCH
Brandi Felser
Favorite
Feng, Wei-Lien

National Health Research Institute
(P 428) MAINTENANCE PEGYLATED LIPOSOMAL DOXORUBICIN VERSUS ACTIVE SURVEILLANCE FOR ADVANCED SOFT TISSUE SARCOMA PATIENTS WHO HAD CONTROLLED DISEASE AFTER STANDARD ANTHRACYCLINE-BASED TREATMENT (MELODY)
Wei-Lien Feng
Favorite
Feng, Xiaolan

Tom Baker Cancer Center
(P 128) ISOCITRATE DEHYDROGENASE 1 (IDH1) MUTATION TESTING IN THE PHASE 3 STUDY OF IVOSIDENIB VS PLACEBO IN IDH1-MUTANT CONVENTIONAL CHONDROSARCOMA (CHONQUER)
Xiaolan Feng
Favorite
Feng, Xiaolan

University of Calgary
(P 395) ERIBULIN IN RECURRENT PRETREATED METASTATIC SOFT TISSUE SARCOMA. A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) REAL WORLD ANALYSIS
Xiaolan Feng
Favorite
Feng, Yi

The Second Hospital of Shanxi Medical University
(P 407) PIMICOTINIB IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): LONG-TERM EFFICACY, SAFETY, AND PATIENT-REPORTED OUTCOMES FROM THE PHASE 3 MANEUVER STUDY
Yi Feng
Favorite
Fenner, Elizabeth

Johns Hopkins University
(P 405) PAN-RAS INHIBITION AS A NOVEL THERAPEUTIC STRATEGY FOR RAS-DRIVEN RHABDOMYOSARCOMA
Elizabeth Fenner
Favorite
Ferguson, Peter

Department of Surgery, Sinai Health
(P 88) THE RAY CHALLENGE: HOW MANY RAY RESECTIONS CAN PATIENTS TOLERATE AND WHICH RAY RESECTIONS AFFECTS FUNCTIONAL OUTCOME THE MOST IN ORTHOPEDIC ONCOLOGY?
Peter Ferguson
Favorite
(P 143) IMPACT OF SURGICAL MARGINS IN CHEST WALL CHONDROSARCOMAS: A CANSARCC STUDY
Peter Ferguson
Favorite
(P 332) MARGINAL EXCISION OF EXTREMITY DEDIFFERENTIATED LIPOSARCOMA WITHOUT RADIATION MAY BE SAFE IN SELECT PATIENTS
Peter Ferguson
Favorite
(P 374) DISTINCT PATTERNS OF METASTATIC SPREAD IN LEIOMYOSARCOMA: A COMPARATIVE ANALYSIS OF TRUNCAL AND EXTREMITY TUMOURS
Peter Ferguson
Favorite
(P 375) DOES STAGED RESECTION WITH TEMPORIZING WOUND VACUUM INFLUENCE LOCAL RECURRENCE RISK? A MULTI-INSTITUTIONAL MATCHED COHORT ANALYSIS
Peter Ferguson
Favorite
Feric Bojic, Elma

Deciphera Pharmaceuticals, LLC
(P 424) AN OPEN-LABEL PHASE 1/2 STUDY OF DCC-3009 MONOTHERAPY IN PATIENTS (PTS) WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR (GIST)
Elma Feric Bojic
Favorite
Fernandez Garrido, Manuel

Hospital Clínic Barcelona
(P 383) MULTIDISCIPLINARY TREATMENT OF INGUINOSCROTAL SARCOMAS: ANALYSIS OF 39 CASES TREATED BY SURGICAL APPROACH
Manuel Fernandez Garrido
Favorite
FERNANDEZ MADRIGAL, LAURA

HOSPITAL JUAN RAMÓN JIMENEZ
(P 321) COMPARATIVE ANALYSIS OF FIRST-LINE DOXORUBICIN-BASED COMBINATION REGIMENS IN METASTATIC LEIOMYOSARCOMA: IMPACT ON SURVIVAL AND DISEASE CONTROL
LAURA FERNANDEZ MADRIGAL
Favorite
Ferrari, Andrea

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 452) EFFECTIVENESS OF ERIBULIN FOR MYXOID PLEOMORPHIC LIPOSARCOMA: INSIGHTS FROM A PATIENT-DERIVED MODEL AND CLINICAL TRANSLATION IN A PATIENT WITH ADVANCED DISEASE
Andrea Ferrari
Favorite
Ferron, Gwenael

OCR
(P 28) ADVANCING PRECISION ONCOLOGY IN SOFT TISSUE SARCOMAS: THE ROLE OF ITRAC IN METASTATIC RISK STRATIFICATION AND TREATMENT PERSONALIZATION
Gwenael Ferron
Favorite
Fetterly, Gerald

Immunome, Inc.
(P 315) ANALYSIS OF CHANGES IN T2-WEIGHTED SIGNAL INTENSITY AND TUMOR VOLUME AND EXPOSURE-RESPONSE IN THE RINGSIDE PHASE 2 STUDY OF VAREGACESTAT FOR DESMOID TUMORS
Gerald Fetterly
Favorite
Fetzer, Erin

The Ohio State University
(P 170) GEMSARC: AN AI BASED PREDICTIVE GENE SIGNATURE FOR GEMCITABINE EFFICACY IN ADVANCED SOFT-TISSUE SARCOMAS
Erin Fetzer
Favorite
(P 408) REAL-WORLD SINGLE-CENTER INSIGHTS INTO CT-DNA DYNAMICS ACROSS SOFT TISSUE SARCOMAS
Erin Fetzer
Favorite
Fice, Michael

Department of Orthopaedic Surgery, University of California Los Angeles
(P 16) MITOCHONDRIAL GENETIC VARIATION ORCHESTRATES COPZ1 TRANSCRIPT HETEROGENEITY AND REVEALS TELOMERE-MEDIATED VULNERABILITIES IN OSTEOSARCOMA
Michael Fice
Favorite
(P 72) COUNTY-LEVEL ASSOCIATIONS BETWEEN AIRBORNE TOXICANT EMISSIONS AND EWING SARCOMA DIAGNOSIS IN THE UNITED STATES
Michael Fice
Favorite
(P 81) ASSESSING PROGNOSTIC FACTORS OF CAUSE-SPECIFIC SURVIVAL IN PATIENTS WITH MALIGNANT GIANT CELL TUMORS: A POPULATION BASED STUDY FROM THE SEER DATABASE
Michael Fice
Favorite
(P 92) PRIMARY TUMOR SIZE AS AN INDEPENDENT PROGNOSTIC FACTOR IN OSTEOSARCOMA: PROPENSITY SCORE-MATCHED ANALYSIS DEMONSTRATES A CONTINUOUS DOSE-RESPONSE RELATIONSHIP
Michael Fice
Favorite
(P 100) THE ROLE OF CANCER TYPE IN THE DEVELOPMENT OF PERIPROSTHETIC JOINT INFECTION IN DISTAL FEMORAL REPLACEMENT
Michael Fice
Favorite
(P 107) IS THERE A BETTER OPTION: INTRAMEDULLARY NAIL VERSUS PLATE OSTEOSYNTHESIS FOR PATHOLOGIC HUMERAL FRACTURES?
Michael Fice
Favorite
(P 108) DISTANCE WEIGHTED MATCHING IN THE QUANTIFICATION OF EXCESS MORBIDITY IN EXTERNAL HEMIPELVECTOMY AND HIP DISARTICULATION
Michael Fice
Favorite
(P 157) INCOME IMPACTS OVERALL BUT NOT CAUSE-SPECIFIC SURVIVAL IN PATIENTS WITH CHONDROSARCOMA: A POPULATION BASED STUDY FROM THE SEER DATABASE
Michael Fice
Favorite
(P 232) IS THERE A ROLE FOR POSITRON EMISSION TOMOGRAPHY IN THE STAGING OF LANGERHANS CELL HISTIOCYTOSIS?
Michael Fice
Favorite
(P 384) PELVIC LOCATION PREDICTS WORSE OUTCOMES IN ALVEOLAR RHABDOMYOSARCOMA: UNDERUSE OF RADIOTHERAPY AND MISSED SURVIVAL BENEFIT
Michael Fice
Favorite
Field, Julie

Dana-Farber Cancer Institute
(P 427) PHASE 1/2 TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF PEEL-224 IN COMBINATION WITH VINCRISTINE AND TEMOZOLOMIDE IN ADOLESCENTS AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY SARCOMAS
Julie Field
Favorite
Fietkau, Rainer

Department of Radiation Oncology, Universitätsstraße 27, 91054 Erlangen, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Germany
(P 288) IDENTIFICATION OF A DNA REPAIR INHIBITOR FOR THE COMBINATION WITH LURBINECTEDIN AND RADIOTHERAPY IN SARCOMA CELL LINES
Rainer Fietkau
Favorite
Fiksen, Lars

Department of Oncology, Herlev University Hospital
(P 319) CARDIOTOXICITY AND OVERALL SURVIVAL IN PATIENTS WITH SARCOMA TREATED WITH DOXORUBICIN, OLARATUMAB AND DEXRAZOXANE: A REAL-WORLD EXPERIENCE IN DENMARK
Lars Fiksen
Favorite
Finetti, pascal

Institut Paoli-Calmettes
(P 59) TARGETING ADORA2B TO HALT METASTASIS IN UNDIFFERENTIATED PLEOMORPHIC SARCOMA: FROM MULTI-OMICS TO THERAPEUTIC INHIBITION
pascal Finetti
Favorite
Fingerle-Rowson, Günter

Tubulis, Inc
(P 34) EXPRESSION OF ONCOFETAL ANTIGEN 5T4 IN SARCOMA SUBTYPES AND PRECLINICAL ACTIVITY OF TUB-030, A NOVEL 5T4-TARGETING ANTIBODY-DRUG CONJUGATE (ADC)
Günter Fingerle-Rowson
Favorite
Fiocco, Marta

Mathematical institute
(P 144) THE RISK OF PATHOLOGICAL FRACTURES AFTER INTRALESIONAL CURETTAGE IN ATYPICAL CARTILAGINOUS TUMOURS: A RETROSPECTIVE COHORT STUDY
Marta Fiocco
Favorite
(P 295) FROM HISTORICAL REFERENCE TO MODERN PRACTICE: WOUND COMPLICATION RATES IN SOFT TISSUE SARCOMA TREATED WITH RADIOTHERAPY ACROSS ERAS
Marta Fiocco
Favorite
Fiore, Marco

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 231) INCREASED LIFETIME RISK (LTR) OF SOFT TISSUE SARCOMAS (STS) IN PATIENTS WITH LOW-RISK GASTROINTESTINAL STROMAL TUMORS (GIST): A RETROSPECTIVE ANALYSIS FROM THE ITALIAN SARCOMA GROUP (ISG)
Marco Fiore
Favorite
(P 307) STRATEGIES FOR DATA QUALITY IN TARPSWG RETROPERITONEAL SARCOMA REGISTRY (RESAR)
Marco Fiore
Favorite
(P 308) IMPACT OF PSOAS MUSCLE RESECTION ON OUTCOMES IN PRIMARY RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA
Marco Fiore
Favorite
(P 309) RETROPERITONEAL LIPOMAS: MULTICENTER CLINICAL EXPERIENCE WITH AN EXTREMELY RARE DISEASE ENTITY
Marco Fiore
Favorite
(P 328) INNOVATING SARCOMA EDUCATION: EARLY OUTCOMES OF THE ITALIAN SOCIETY OF SURGICAL ONCOLOGY (SICO) SARCOMA SOCIAL MULTI-PLATFORM JOURNAL CLUB INITIATIVE
Marco Fiore
Favorite
Fischer, Hannah

Sarcoma Unit, Department of Surgery, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University
(P 312) APOSST: A PROSPECTIVE TRIAL TO EVALUATE ACUPUNCTURE AFTER SURGERY OF EXTREMITY SOFT TISSUE TUMORS
Hannah Fischer
Favorite
Fisher-Wellman, Kelsey

Wake Forest University
(P 259) PRECLINICAL MODELING OF CHEMOTHERAPY RELEASE IDENTIFIES MITOCHONDRIAL ADAPTATIONS IN DOXORUBICIN TREATED OSTEOSARCOMA
Kelsey Fisher-Wellman
Favorite
Fitzgibbon, Gillian

St Vincent's University Hospital
(P 211) HEALTH-RELATED QUALITY OF LIFE IN IRISH SARCOMA PATIENTS
Gillian Fitzgibbon
Favorite
(P 213) FINANCIAL TOXICITY IN IRISH SARCOMA CARE: A SINGLE-CENTRE ANALYSIS
Gillian Fitzgibbon
Favorite
Fjaestad, Klaire Yixin

Herlev and Gentofte Hospital
(P 36) MODULATION OF THE SARCOMA MICROENVIRONMENT THROUGH β-ADRENERGIC BLOCKADE
Klaire Yixin Fjaestad
Favorite
Fleuren, Emmy

Children's Cancer Institute
(P 11) ESTABLISHMENT, CHARACTERIZATION AND RESEARCH APPLICATION OF EIGHT NOVEL PATIENT-DERIVED OSTEOSARCOMA CELL LINES
Emmy Fleuren
Favorite
(P 266) TARGETING THE DNA DAMAGE RESPONSE TO ADVANCE PRECISION THERAPIES IN PAEDIATRIC SARCOMA
Emmy Fleuren
Favorite
Flojo, Renceh

Stanford University
(P 37) DISSECTING THE TUMOR MICROENVIRONMENT OF UTERINE LEIOMYOSARCOMAS FOR TARGETED DRUG PREDICTIONS
Renceh Flojo
Favorite
FLOR ONCALA, MARIA JOSE

HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO
(P 115) SINGLE-CENTER EXPERIENCE WITH TYROSIN KINASA INHIBITORS IN ADVANCED BONE SARCOMA: EFFICACY AND SAFETY OUTCOMES
MARIA JOSE FLOR ONCALA
Favorite
(P 321) COMPARATIVE ANALYSIS OF FIRST-LINE DOXORUBICIN-BASED COMBINATION REGIMENS IN METASTATIC LEIOMYOSARCOMA: IMPACT ON SURVIVAL AND DISEASE CONTROL
MARIA JOSE FLOR ONCALA
Favorite
Flor, Lior

University of British Columbia
(P 178) TREATMENT RESPONSE AND SURVIVAL OUTCOMES IN GASTROINTESTINAL STROMAL TUMORS FOLLOWING NEOADJUVANT THERAPY
Lior Flor
Favorite
Florou, Vaia

Huntsman Cancer Institute
(P 01) FEASIBILITY OF A QUANTITATIVE METHYLATION-BASED CTDNA ASSAY IN PATIENTS WITH ADVANCED SARCOMAS
Vaia Florou
Favorite
Floyd, Warren

M.D. Anderson Cancer Center, University of Texas
(P 58) PLK1 AS A VULNERABLE TARGET OF BAP1-DRIVEN UNDIFFERENTIATED PLEOMORPHIC SARCOMAS
Warren Floyd
Favorite
Flynn, Samantha

Department of Pathology, Massachusetts General Hospital, Harvard Medical School
(P 45) MONITORING EWSR1 FUSIONS IN SARCOMA PATIENTS USING PERSONALIZED LIQUID BIOPSY ASSAYS
Samantha Flynn
Favorite
Fofah, Oluwatosin

Epidemiology, Clinical Safety and Pharmacovigilance, Daiichi Sankyo, Inc., Basking Ridge, NJ, USA
(P 336) PEXIDARTINIB RISK EVALUATION AND MITIGATION STRATEGY PROGRAM: 5-YEAR RETROSPECTIVE HEPATIC SAFETY ASSESSMENT
Oluwatosin Fofah
Favorite
(P 381) KNOWLEDGE, ATTITUDES, AND BEHAVIOR OF HEALTHCARE PROVIDERS ENROLLED IN THE PEXIDARTINIB RISK MITIGATION AND EVALUATION PROGRAM
Oluwatosin Fofah
Favorite
Fojtů, Michaela

SOTIO Biotech a.s.
(P 257) TARGETING LEUCINE-RICH REPEAT-CONTAINING PROTEIN 15 (LRRC15): SOT106 ANTIBODY-DRUG CONJUGATE FOR SOFT TISSUE SARCOMA AND OSTEOSARCOMA TREATMENT
Michaela Fojtů
Favorite
Foppele, Geraldien Florine

Netherlands Cancer Institute
(P 295) FROM HISTORICAL REFERENCE TO MODERN PRACTICE: WOUND COMPLICATION RATES IN SOFT TISSUE SARCOMA TREATED WITH RADIOTHERAPY ACROSS ERAS
Geraldien Florine Foppele
Favorite
Fordham, Ashleigh

Children's Cancer Institute
(P 11) ESTABLISHMENT, CHARACTERIZATION AND RESEARCH APPLICATION OF EIGHT NOVEL PATIENT-DERIVED OSTEOSARCOMA CELL LINES
Ashleigh Fordham
Favorite
Ford, Marvella

Medical University of South Carolina
(P 279) IMPACT OF PREOPERATIVE 5-DAY HYPOFRACTIONATED RADIOTHERAPY (HFRT) FOR SOFT TISSUE SARCOMA (STS) ON BARRIERS TO TREATMENT AT A HIGH-VOLUME SARCOMA CENTER (HV-SC)
Marvella Ford
Favorite
Formiga, Maria N. C.

AC Camargo Cancer Center
(P 155) BRCA2-MUTATED CONVENTIONAL CHONDROSARCOMA RESPONDING TO PARP INHIBITION: A CASE REPORT
Maria N. C. Formiga
Favorite
Fröhling, Stefan

German Cancer Research Center
(P 454) TREATMENT PATTERNS AND OUTCOMES IN RADIATION-INDUCED SARCOMA: FIRST RESULTS OF THE TETRIS-PROJECT - A MULTIMODAL RETROSPECTIVE ANALYSIS FROM A TERTIARY CENTER
Stefan Fröhling
Favorite
(P 455) DEVELOPMENT OF PATIENT-CENTERED INFORMATION MATERIAL ON RADIATION-INDUCED SARCOMA: QUALITATIVE RESULTS FROM FOCUS GROUPS OF THE TETRIS-PROJECT
Stefan Fröhling
Favorite
Frölich, Matthias

Department of Radiology and Nuclear Medicine, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University
(P 367) ADHERENCE TO GERMAN SARCOMA GUIDELINE FOR MRI SEQUENCING IN SOFT TISSUE SARCOMA: EVALUATION OF IMAGING PRACTICES AND COMPLIANCE
Matthias Frölich
Favorite
Franca, Guilherme

Grupo Oncoclinicas
(P 285) MULTICENTER STUDY OF SPATIALLY FRACTIONATED RADIOTHERAPY (LATTICE) FOR LARGE-VOLUME RADIORESISTANT SARCOMAS
Guilherme Franca
Favorite
Franca, Monique

Grupo Oncoclinicas
(P 285) MULTICENTER STUDY OF SPATIALLY FRACTIONATED RADIOTHERAPY (LATTICE) FOR LARGE-VOLUME RADIORESISTANT SARCOMAS
Monique Franca
Favorite
Franceschi, Dido

University of Miami Hospital, Department of Surgical Oncology
(P 201) METASTATIC PATTERNS, TREATMENT MODALITIES, AND OVERALL SURVIVAL IN OLIGOMETASTATIC GIST: A SINGLE-CENTER RETROSPECTIVE STUDY
Dido Franceschi
Favorite
Franchini, Melania

Columbia University Irving Medical Center
(P 25) IDENTIFICATION AND VALIDATION OF NON-GENETICALLY ENCODED VULNERABILITIES IN EWING SARCOMA
Melania Franchini
Favorite
Franke, Bianca

Association of German Tumor Centers, ADT
(P 204) ANALYSIS OF QUALITY INDICATORS OF SOFT TISSUE SARCOMA TREATMENT WITH CANCER REGISTRY DATA IN GERMANY 2015-2021
Bianca Franke
Favorite
Frankel, Daniel

Colorfix
(P 135) EXPLORING THE ROLE OF CLUSTER OF DIFFERENTIATION 44 IN CHONDROSARCOMA
Daniel Frankel
Favorite
Franza, Andrea

ASST Lariana - Ospedale Sant'Anna
(P 331) MAINTENANCE THERAPY (M-TP) WITH DACARBAZINE (DTIC) AFTER FIRST-LINE ANTHRACYCLINE-BASED DOUBLET IN ADVANCED LEIOMYOSARCOMA (LMS) PATIENTS (PTS): OUTCOMES OF A CASE SERIES IN A SINGLE REFERRAL CENTER
Andrea Franza
Favorite
Frazee, Katherine

Mass Eye and Ear
(P 62) INTRAOPERATIVE BONE AND SOFT TISSUE TUMOR MARGIN IDENTIFICATION WITH FLUORESCENCE LIFETIME (FLT) IMAGING
Katherine Frazee
Favorite
Frega, Giorgio

IRCCS Rizzoli Orthopaedic Institute
(P 18) ESTABLISHMENT AND CHARACTERIZATION OF A NOVEL PRIMARY CELL LINE FROM A BONE METASTASIS OF OSTEOSARCOMA
Giorgio Frega
Favorite
(P 139) IMMUNOGENOMIC PROFILING OF CHONDROSARCOMA REVEALS DISTINCT IMMUNE PHENOTYPES AND PROGNOSTIC MUTATIONS
Giorgio Frega
Favorite
FRENOIS, Francois-Xavier

Institut Universitaire du Cancer de Toulouse
(P 12) DNA REPLICATION STRESS AND DEFICIENT HOMOLOGOUS RECOMBINATION IN OSTEOSARCOMA RISK AND THERAPY
Francois-Xavier FRENOIS
Favorite
Frezza, Anna Maria

Fondazione IRCCS Istituto Nazionale Tumori
(P 446) GDF-15 AS A PROGNOSTIC FACTOR IN PATIENTS WITH EPITHELIOID HEMANGIOENDOTHELIOMA
Anna Maria Frezza
Favorite
(P 447) PAIN ASSESSMENT CRITERIA (PAC) ANTICIPATE RECIST PROGRESSION AND CORRELATE WITH BLOOD LEVELS OF GROWTH DIFFERENTIATION FACTOR 15 (GDF15) IN EPITHELIOID HEMANGIOENDOTHELIOMA (EHE)
Anna Maria Frezza
Favorite
(P 458) BETWEEN LYMPHOMAS AND SARCOMAS: A RETROSPECTIVE, MULTI-INSTITUTIONAL STUDY FROM THE ITALIAN SARCOMA GROUP (ISG) ON HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS (HDCN)
Anna Maria Frezza
Favorite
Friedman, Elizabeth

University of Kansas Medical Center
(P 366) WOUND COMPLICATIONS AFTER ULTRA-HYPOFRACTIONATED NEOADJUVANT RADIATION FOR SOFT TISSUE SARCOMA: WHAT IS OPTIMAL SURGICAL TIMING?
Elizabeth Friedman
Favorite
Fritchie, Karen

Cleveland Clinic
(P 284) THE IMPACT OF SARCOMA SBRT ON THE IMMUNE SYSTEM: EARLY RESULTS FROM A PROSPECTIVE TRIAL
Karen Fritchie
Favorite
Frohlich, Dean

Sarcoma Foundation of America
(P 209) SARCOMA PATIENT COMMUNITY DATA COLLABORATION TO ADVANCE RESEARCH
Dean Frohlich
Favorite
Fuchs, Bruno

LUKS University Hospital, Swiss Sarcoma Netowrk
(P 215) SHAPEHUB: A MULTICENTRE REAL-WORLD-TIME DATA PLATFORM WITH DIGITAL TWIN ENGINE FOR A LEARNING HEALTH SYSTEM IN SARCOMA
Bruno Fuchs
Favorite
(P 282) LOCAL FAILURE ANALYSIS OF SOFT TISSUE SARCOMA TREATED WITH PREOPERATIVE ULTRA-HYPOFRACTIONATED RADIATION: UPDATE
Bruno Fuchs
Favorite
(P 283) PALLIATIVE LATTICE RADIATION THERAPY IN SOFT TISSUE SARCOMA VERSUS CARCINOMA AND MELANOMA: OUTCOME COMPARISON
Bruno Fuchs
Favorite
(P 285) MULTICENTER STUDY OF SPATIALLY FRACTIONATED RADIOTHERAPY (LATTICE) FOR LARGE-VOLUME RADIORESISTANT SARCOMAS
Bruno Fuchs
Favorite
Fuchs, Jörg

University Children's Hospital
(P 250) OUTCOME OF INFANTS WITH RHABDOMYOSARCOMA: A REPORT FROM THE INTERNATIONAL SOFT TISSUE SARCOMA CONSORTIUM
Jörg Fuchs
Favorite
Fuchs, Joseph

McGaw Medical Center of Northwestern University
(P 353) TREATMENT OF ADVANCED EPITHELIOID SARCOMA WITH COMBINATION TAZEMETOSTAT AND PEMBROLIZUMAB
Joseph Fuchs
Favorite
(P 429) SINGLE-ARM, OPEN-LABEL PHASE II TRIAL OF XL092 (ZANZALINTINIB) IN PATIENTS WITH ADVANCED LEIOMYOSARCOMA: TRIAL IN PROGRESS
Joseph Fuchs
Favorite
Fujiwara, Tomohiro

Okayama University Hospital
(P 79) AGE-BASED TREATMENT PATTERNS AND OUTCOMES OF LOCALIZED HIGH-GRADE OSTEOSARCOMA FROM A NATIONWIDE DATABASE: WHAT IS THE OPTIMAL STRATEGY FOR PATIENTS OLDER THAN 40 YEARS?
Tomohiro Fujiwara
Favorite
Fujiwara, Toshifumi

Kyushu University
(P 472) LANDSCAPE OF ULTRA-RARE SARCOMAS: A NATIONWIDE STUDY FOR EPIDEMIOLOGY AND PROGNOSIS
Toshifumi Fujiwara
Favorite
Fumagalli, Elena

Medical Oncology Unit 2, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
(P 231) INCREASED LIFETIME RISK (LTR) OF SOFT TISSUE SARCOMAS (STS) IN PATIENTS WITH LOW-RISK GASTROINTESTINAL STROMAL TUMORS (GIST): A RETROSPECTIVE ANALYSIS FROM THE ITALIAN SARCOMA GROUP (ISG)
Elena Fumagalli
Favorite
Fumagalli, Elena

Fondazione IRCCS Istituto nazionale dei tumori
(P 331) MAINTENANCE THERAPY (M-TP) WITH DACARBAZINE (DTIC) AFTER FIRST-LINE ANTHRACYCLINE-BASED DOUBLET IN ADVANCED LEIOMYOSARCOMA (LMS) PATIENTS (PTS): OUTCOMES OF A CASE SERIES IN A SINGLE REFERRAL CENTER
Elena Fumagalli
Favorite
Funovics, Philipp

Medical University of Vienna
(P 86) CARBON FIBRE-REINFORCED PEEK IMPLANTS FOR TUMORS OF THE SPINE
Philipp Funovics
Favorite
Funovics, Philipp

University Hospital Vienna
(P 151) SHOULD WE USE ADJUVANT CHEMOTHERAPY IN PATIENTS WITH LOCALIZED DEDIFFERENTIATED CHONDROSARCOMA (DDCS) OF THE PELVIS? AN ANALYSIS BY THE PELVIC DDCS STUDY GROUP
Philipp Funovics
Favorite
Fura, Samuel

University of Miami School of Medicine
(P 362) SHOULD PAZOPANIB BE USED AS A MAINTENANCE THERAPY TO IMPROVE RECURRENCE-FREE SURVIVAL AND OVERALL SURVIVAL IN PATIENTS WHO RECEIVED MAI IN SOFT TISSUE SARCOMA?
Samuel Fura
Favorite
Futreal, P Andrew

MD Anderson Cancer Center
(P 47) EWSR1::WT1 FUSION ONCOPROTEIN ACTIVITY SHAPES LINEAGE HETEROGENEITY IN DESMOPLASTIC SMALL ROUND CELL TUMORS
P Andrew Futreal
Favorite